In two randomly selected plasma samples, which included a patient with a CNS demyelinating disorder and a patient with Susac syndrome, we found that the addition of anetumab-conjugated Dynabeads® significantly reduced the concentration of sMSLN in plasma samples as detected by a MSLN ELISA (p < 0.05). Here, MSLN is linked to Susac syndrome.